Hot Features
Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LR... Oncodesign Precision Medicine Société anonyme, a biopharmaceutical company, engages in the precision medicine business. The company’s product pipeline consist of OPM-101, a RIPK2 inhibitor for the treatment of inflammatory bowel disease and immuno-oncology; OPM-102 to treat cancer; and OPM-201, a LRRK2 inhibitor for the treatment of Parkinson’s disease. It also focuses on the development of a radiotheranostic molecule portfolio for the diagnosis and the treatment of advanced digestive cancers, as well as on developing treatment for pancreatic and other cancers. Oncodesign Precision Medicine Société anonyme was founded in 1995 and is based in Dijon, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.003 | -0.869565217391 | 0.345 | 0.351 | 0.341 | 3309 | 0.34852166 | DE |
| 4 | -0.082 | -19.3396226415 | 0.424 | 0.424 | 0.34 | 19871 | 0.37511532 | DE |
| 12 | -0.142 | -29.3388429752 | 0.484 | 0.499 | 0.34 | 17213 | 0.42218755 | DE |
| 26 | -0.043 | -11.1688311688 | 0.385 | 0.758 | 0.34 | 35451 | 0.54196103 | DE |
| 52 | 0.052 | 17.9310344828 | 0.29 | 0.912 | 0.283 | 30347 | 0.52046106 | DE |
| 156 | -1.018 | -74.8529411765 | 1.36 | 2.39 | 0.28 | 17079 | 0.8269508 | DE |
| 260 | -0.648 | -65.4545454545 | 0.99 | 2.39 | 0.28 | 15932 | 0.90043675 | DE |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.